A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma

Trial Profile

A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record
    • 02 Jun 2015 Primary endpoint has not been met. (Objective radiologic response rate (complete or partial response) assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top